DASH vs NRIX · P/E 76, rev $13.72B vs rev $54.5M
DoorDash, Inc. Class A Common Stock (DASH) versus Nurix Therapeutics Inc (NRIX) — a side-by-side from cached financials, not a winner call.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Nurix Therapeutics Inc (NRIX) is a biotechnology company listed on NASDAQ.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Latest reported NRIX revenue for 2024-11-30 was $54.5M. Net income was -$193.6M. Revenue was down 29.1% from 2023-11-30 to 2024-11-30. NRIX currently screens at market cap $1.77B.
DASH currently screens at market cap $69.41B and trailing P/E 75.9. NRIX currently screens at market cap $1.77B.
Not investment advice. Open the DASH and NRIX stock pages for the full models.
Not investment advice.